Progressive myocardial injury is associated with mortality in the acute respiratory distress syndrome

Thomas S. Metkus, Eliseo Guallar, Lori Sokoll, David A. Morrow, Gordon Tomaselli, Roy Brower, Bo Soo Kim, Steven Schulman, Frederick K. Korley

PII: S0883-9441(18)30832-3
DOI: doi:10.1016/j.jcrc.2018.08.009
Reference: YJCRC 53001

To appear in: *Journal of Critical Care*

Please cite this article as: Thomas S. Metkus, Eliseo Guallar, Lori Sokoll, David A. Morrow, Gordon Tomaselli, Roy Brower, Bo Soo Kim, Steven Schulman, Frederick K. Korley , Progressive myocardial injury is associated with mortality in the acute respiratory distress syndrome. Yjcrc (2018), doi:10.1016/j.jcrc.2018.08.009

Progressive myocardial injury is associated with mortality in the acute respiratory distress syndrome

Thomas S. Metkus MD[1,*] tmetkus1@jhmi.edu, Eliseo Guallar MD DrPH[2], Lori Sokoll PhD[3] ,David A. Morrow MD MPH[4], Gordon Tomaselli MD[1], Roy Brower MD[5], Bo Soo Kim MD[5] Steven Schulman MD[1], and Frederick K. Korley MD PhD[6]

[1]Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine
[2]Departments of Epidemiology and Medicine and Welch Center for Prevention, Epidemiology, and Clinical Research; Johns Hopkins Bloomberg School of Public Health
[3]Department of Pathology, Johns Hopkins University School of Medicine
[4]Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School
[5]Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine
[6]Department of Emergency Medicine, University of Michigan Medical School

Disclosures: Abbott Laboratories provided reagents and financial support for the study; the study was designed and executed solely by the study investigators without industry involvement. Dr. Sokoll received further research funding from Abbott Laboratories. Dr. Morrow reports grants to the TIMI Study Group from Abbott Laboratories, Amgen, AstraZeneca, Daiichi Sankyo, Eisai, GlaxoSmithKline, Merck, Novartis, Roche Diagnostics, Singulex and consultant fees from Abbott Laboratories, AstraZeneca, diaDexus, GlaxoSmithKline, Merck, Peloton, Roche Diagnostics, and Verseon. Dr. Metkus performs consulting unrelated to this subject matter for BestDoctors Inc and Oakstone/EBIX. Dr. Metkus received royalties for a textbook publication from McGraw-Hill publishing, unrelated to this subject matter. From 2014-2016, Dr. Metkus received salary support from NIH-NHLBI grant number T32-HL007227-40.

[*]**Corresponding author at:** Johns Hopkins Hospital, 600 N. Wolfe Street; Blalock 524 D2; Baltimore, MD 21287; 410-955-5000

TM, EG, SS and FK designed the study. All authors contributed to analysis planning, performance of the analysis and interpretation of results. All authors participated in drafting the manuscript and providing critical commentary. All authors provided final approval of the submitted manuscript.

Abstract

Purpose: Myocardial injury connotes worse prognosis in the Acute Respiratory Distress Syndrome (ARDS), however the prognostic connotation of changes in cardiac troponin (cTn) levels in ARDS patients is not known.

Methods: We performed a study of 908 ARDS patients enrolled in two previously completed ARDS Network trials. We obtained plasma samples via the NIH BIOLINCC repository and measured cTn using the ARCHITECT STAT high sensitivity troponin-I assay (Abbott Laboratories) at trial day 0